• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙型肝炎病毒感染是印度严重肝病的主要病因。

Hepatitis C virus infection is the major cause of severe liver disease in India.

作者信息

Tandon B N, Irshad M, Acharya S K, Joshi Y K

机构信息

Department of Gastroenterology, All-India Institute of Medical Sciences, New Delhi.

出版信息

Gastroenterol Jpn. 1991 Jul;26 Suppl 3:192-5. doi: 10.1007/BF02779297.

DOI:10.1007/BF02779297
PMID:1909266
Abstract

The present study describes the status of hepatitis C virus infection in 167 patients with severe forms of liver diseases in India. The anti-HCV positivity rate was recorded as 43%, 47%, and 42% in patients with FHF, SAHF, and CAH respectively. HBV and HCV coinfection was recorded in 28% of FHF, 43% of SAHF and 75% of the CAH cases. Superinfection of HCV in HBsAg carriers was recorded in the 54% cases of FHF, 60% of SAHF and 42% of the CAH. None of these 167 patients was positive of HAV-IgM. Further, 27.7% of FHF, 26.4% of SAHF and 15.2% of CAH cases were neither HBV nor HCV markers positive. These can be labelled as non-A, non-B and non-C infections.

摘要

本研究描述了印度167例重症肝病患者的丙型肝炎病毒感染状况。在暴发性肝衰竭(FHF)、慢加急性肝衰竭(SAHF)和慢性活动性肝炎(CAH)患者中,抗-HCV阳性率分别记录为43%、47%和42%。FHF患者中28%、SAHF患者中43%以及CAH患者中75%存在HBV和HCV合并感染。HBsAg携带者中HCV重叠感染在FHF病例中占54%,SAHF中占60%,CAH中占42%。这167例患者中无一例HAV-IgM呈阳性。此外,FHF病例中27.7%、SAHF病例中26.4%以及CAH病例中15.2%既无HBV也无HCV标志物呈阳性。这些可被标记为非甲、非乙、非丙型感染。

相似文献

1
Hepatitis C virus infection is the major cause of severe liver disease in India.丙型肝炎病毒感染是印度严重肝病的主要病因。
Gastroenterol Jpn. 1991 Jul;26 Suppl 3:192-5. doi: 10.1007/BF02779297.
2
Hepatitis D virus (HDV) infection in severe forms of liver diseases in north India.印度北部严重肝病中的丁型肝炎病毒(HDV)感染
Eur J Gastroenterol Hepatol. 1996 Oct;8(10):995-8. doi: 10.1097/00042737-199610000-00011.
3
Status of hepatitis viral markers in patients with acute and chronic liver diseases in northern India.印度北部急慢性肝病患者的肝炎病毒标志物状况
Intervirology. 1994;37(6):369-72. doi: 10.1159/000150404.
4
Anti-hepatitis C virus antibody prevails in fulminant hepatic failure.抗丙型肝炎病毒抗体在暴发性肝衰竭中普遍存在。
Gastroenterol Jpn. 1990 Feb;25(1):32-5. doi: 10.1007/BF02785327.
5
Detection of anti-hepatitis C virus antibody in fulminant hepatic failure.暴发性肝衰竭中抗丙型肝炎病毒抗体的检测
Gastroenterol Jpn. 1991 Jul;26 Suppl 3:212-5. doi: 10.1007/BF02779302.
6
Prevalence and presentation of hepatitis C related chronic liver disease in southern India.印度南部丙型肝炎相关慢性肝病的患病率及临床表现
J Trop Med Hyg. 1995 Jun;98(3):161-5.
7
Comparative analysis of HBV and HCV infection in hepatocellular carcinoma and chronic liver disease--an autopsy based study.肝细胞癌和慢性肝病中HBV与HCV感染的比较分析——一项基于尸检的研究
Indian J Pathol Microbiol. 2006 Jul;49(3):357-61.
8
Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies.血液系统恶性肿瘤患儿的严重肝脏疾病是由乙肝病毒而非丙肝病毒引起的。
Hematol J. 2003;4(5):321-7. doi: 10.1038/sj.thj.6200300.
9
Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.通过性传播感染艾滋病毒患者中隐匿性乙型和丙型肝炎的患病率。
Trop Gastroenterol. 2007 Jan-Mar;28(1):19-23.
10
Epidemiology, natural history, and treatment of hepatitis B virus and hepatitis C virus coinfection.乙型肝炎病毒与丙型肝炎病毒合并感染的流行病学、自然史及治疗
Minerva Gastroenterol Dietol. 2006 Jun;52(2):145-55.

引用本文的文献

1
Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony.HBV/HCV合并感染的当前概念:共存,但未必和谐。
Curr Hepat Rep. 2010;9(4):260-269. doi: 10.1007/s11901-010-0060-4.
2
Overview of substance abuse and hepatitis C virus infection and co-infections in India.印度物质滥用和丙型肝炎病毒感染及合并感染概述。
J Neuroimmune Pharmacol. 2010 Dec;5(4):496-506. doi: 10.1007/s11481-010-9227-6. Epub 2010 Jun 19.
3
Hepatitis C in India.印度的丙型肝炎。

本文引用的文献

1
Subacute hepatic failure; is it a distinct entity?亚急性肝衰竭;它是一种独立的疾病实体吗?
J Clin Gastroenterol. 1982 Aug;4(4):343-6, 362-4. doi: 10.1097/00004836-198208000-00010.
2
Clinical and prognostic differences in fulminant hepatitis type A, B and non-A non-B.甲型、乙型和非甲非乙型暴发性肝炎的临床及预后差异
Gut. 1983 Dec;24(12):1194-8. doi: 10.1136/gut.24.12.1194.
3
A low cost micro-ELISA test for hepatitis-B surface antigen.一种用于检测乙型肝炎表面抗原的低成本微型酶联免疫吸附测定试验。
J Biosci. 2008 Nov;33(4):465-73. doi: 10.1007/s12038-008-0065-0.
4
Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection.
Dig Dis Sci. 2004 Feb;49(2):281-8. doi: 10.1023/b:ddas.0000017452.85668.8d.
5
Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.
J Gastroenterol. 2002;37 Suppl 13:65-8. doi: 10.1007/BF02990102.
Trop Gastroenterol. 1984 Jul-Sep;5(3):142-8.
4
Acute liver failure. Experience with 145 patients.急性肝衰竭。145例患者的经验。
J Clin Gastroenterol. 1986 Dec;8(6):664-8. doi: 10.1097/00004836-198612000-00016.
5
Fibronectin in acute and subacute hepatic failure.急性和亚急性肝衰竭中的纤连蛋白
J Clin Gastroenterol. 1989 Jun;11(3):314-9. doi: 10.1097/00004836-198906000-00014.
6
Antibodies to hepatitis C virus.丙型肝炎病毒抗体
Lancet. 1989 Aug 5;2(8658):324-5. doi: 10.1016/s0140-6736(89)90501-1.
7
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.从经血传播的非甲非乙型病毒性肝炎基因组中分离出一个cDNA克隆。
Science. 1989 Apr 21;244(4902):359-62. doi: 10.1126/science.2523562.
8
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.一种针对人类非甲非乙型肝炎主要致病病毒的循环抗体检测方法。
Science. 1989 Apr 21;244(4902):362-4. doi: 10.1126/science.2496467.
9
Hepatitis virus non-A, non-B: the cause of a major public health problem in India.非甲非乙型肝炎病毒:印度一个重大公共卫生问题的病因
Bull World Health Organ. 1985;63(5):931-4.
10
Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis.从引起肠道传播的非甲非乙型肝炎的病毒中分离出一种互补脱氧核糖核酸。
Science. 1990 Mar 16;247(4948):1335-9. doi: 10.1126/science.2107574.